18 September 2025
Our molecules, available for free to foster independent research, exhibit high in vitro potency against their target proteins and strong selectivity against other proteins within the same target family. Thanks to our collaboration with the Structural Genomics Consortium (SGC), researchers can now access enhanced data generated using the open-source PRESTO-TANGO selectivity screen (parallel receptorome expression and screening via transcriptional output, with transcriptional activation following arrestin translocation)1. The assay methodology was established by the Psychoactive Drug Screening Program (PDSP)2, a global resource that provides a number of different open-source screens. opnMe initially offers these additional selectivity data for a subset of twelve molecules—all available for free.
The PRESTO-TANGO selectivity screen allows for the parallel and simultaneous interrogation of the druggable human GPCRome (G protein-coupled receptors of the humane genome). It employs standardized and robust methodologies to evaluate compound interactions with essentially any of the non-olfactory GPCRs, providing researchers with high-quality pharmacological data to better understand selectivity and off-target effects.
This new data will eventually be applied to all molecules that Boehringer Ingelheim has generously donated to the SGC’s chemical probes program, further strengthening their utility for scientific exploration. With this first release, we have updated the data for twelve molecules3. By providing deeper insights into selectivity profiles, we aim to empower researchers to advance their studies with high-quality tools and information.
Access all selectivity data for all molecules here and browse through our molecules to order them for free for your research.
Access the full selectivity dataset
No registration required for download
Reference
- Kroeze W. K., Sassano M. F., Huang X. P., Lansu K., McCorvy J. D., Giguère P. M., Sciaky N., Roth B. L. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRomeNat Struct Mol Biol. 2015, 22(5):362-9. DOI, PubMed.
- PDSP - NIMH Psychoactive Drug Screening Program
- Molecules covered: Autotaxin (ATX) inhibitor, CCR1 antagonist, Chymase inhibitor, FAS inhibitor, FLAP antagonist, Glucocorticoid receptor agonist, HCV protease inhibitor, IKKβ inhibitor, LFA-1 antagonist, MMP13 inhibitor, NHE1 inhibitor, sEH inhibitor
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About opnMe:
opnMe.com, the open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights into disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, our “Molecules to Order” are freely available to the scientific community to help unlock and fulfill their full potential. With our “opn2EXPERTS” program, we also enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs.